Načítá se...
Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment
INTRODUCTION: Plasma kallikrein is a mediator of vascular leakage and inflammation. Activation of plasma kallikrein can induce features of diabetic macular edema (DME) in preclinical models. Human vitreous shows elevated plasma kallikrein levels in patients with DME. Because of the incomplete respon...
Uloženo v:
| Vydáno v: | Expert Opin Investig Drugs |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7265898/ https://ncbi.nlm.nih.gov/pubmed/31985300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2020.1723078 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|